Business context and reporting period
Verrica Pharmaceuticals Inc. filed this Form 10-K for the fiscal year ended December 31, 2023; it is an annual report, not a standalone fourth-quarter report. Verrica is a dermatology therapeutics company. Its first approved product, YCANTH (cantharidin 0.7% topical solution), was FDA-approved in July 2023 for molluscum contagiosum in patients aged two and older and launched in the United States in August. The company also has development programs for YCANTH in common and external genital warts, VP-315 for dermatological oncology, and VP-103 for plantar warts.
Financial and operating highlights
| Metric | 2023 | 2022 |
|---|---|---|
| Total revenue | $5.1 million | $9.0 million |
| Product revenue, net | $4.7 million | None |
| Collaboration revenue | $0.5 million | $9.0 million |
| Operating expenses | $70.9 million | $30.3 million |
| Operating loss | $65.8 million | $21.3 million |
| Net loss | $67.0 million | $24.5 million |
| Net loss per share, basic and diluted | $1.48 | $0.72 |
| Net cash used in operating activities | $38.6 million | $18.7 million |
Revenue and comparability: 2023 product revenue reflects initial YCANTH sales to distributor FFF Enterprises. 2022 collaboration revenue included an $8.0 million Torii development milestone; the lower 2023 total revenue therefore reflects both the absence of that milestone and the early stage of the U.S. product launch. YCANTH is currently sold through a single distributor, creating customer concentration.
Expenses and margins: SG&A increased $29.9 million to $47.3 million, mainly from commercial launch activities, sales-force ramp-up, marketing, and stock-based compensation. R&D rose $8.1 million to $20.3 million, primarily due to manufacturing and development work and VP-315 clinical costs. Reported product cost was $0.3 million against $4.7 million of net product revenue, but this launch-stage margin is not representative: certain pre-approval inventory and related costs had already been expensed as R&D. The filing says product cost would have been $0.5 million if specified previously expensed costs were included.
Cash, liquidity, and debt: Cash and cash equivalents were $69.5 million at year-end, up from $34.3 million. Current assets were $77.5 million and current liabilities $17.0 million. Operating cash use was $38.6 million; financing provided $74.2 million, including $44.1 million net proceeds from the OrbiMed facility and $30.3 million net proceeds from a 2023 equity and pre-funded warrant offering. The company carried $42.9 million of long-term debt, net of discount and issuance costs, from a $50.0 million initial OrbiMed borrowing. The facility has a July 2028 maturity and a floating rate of the higher of one-month SOFR or 4%, plus 8%; additional borrowing tranches are subject to revenue targets. The company must maintain at least $10 million of unrestricted cash under the facility.
Other notable items: The company recorded a $2.5 million loss on disposal of an assembly and packaging line after determining that the cost to upgrade it was too high. Stock-based compensation was $14.4 million, including $8.8 million for vested restricted stock units. Accumulated deficit was $230.4 million. The company reported no income tax provision, with a full valuation allowance against net deferred tax assets.
Material changes versus the prior comparable period
- YCANTH moved from development to FDA-approved U.S. commercialization in 2023, generating $4.7 million in initial net product revenue.
- Total revenue fell $3.9 million, chiefly because 2022 included the $8.0 million Torii milestone; Torii supply and development activity contributed $0.5 million in 2023.
- Net loss widened by $42.5 million to $67.0 million, with commercial launch spending, higher R&D, and the asset disposal loss among the drivers.
- Operating cash use increased by $19.9 million. Year-end cash rose because equity and debt financing more than offset operating and investing cash outflows.
- The company replaced its previously repaid debt facility with the OrbiMed secured credit facility and issued 518,551 warrants to the lender.
Outlook, risks, and contingencies
- Management believes year-end cash of $69.5 million will support planned operations into the second quarter of 2025. This is an estimate based on assumptions; the company expects continued losses and says substantial additional financing will be needed.
- Management plans continued commercialization of YCANTH and further development of the pipeline. VP-315 Phase 2 topline results were expected in the first half of 2024. For common warts, FDA alignment on a pivotal Phase 3 plan was reported, with further FDA guidance planned; timing of trials for external genital and plantar warts remained undetermined.
- YCANTH’s permanent HCPCS J-code, J7354, was scheduled to take effect April 1, 2024. The company reported positive coverage decisions representing more than 200 million U.S. covered lives, but coverage and reimbursement may vary by payer.
- Risks include commercialization and reimbursement uncertainty, competition, continued losses and financing needs, debt covenants and revenue conditions on undrawn facility tranches, and reliance on third parties for manufacturing. Cantharidin and certain applicator components depend on suppliers, including a cantharidin source in China; scaling synthetic cantharidin production remains uncertain.
- FDA-approved Zelsuvmi, a competing molluscum treatment, was expected to become commercially available in the second half of 2024. Compounded cantharidin may also compete in circumstances permitted by FDA rules.
- A putative securities class action remains pending. The court allowed claims concerning statements made in May and June 2021 to proceed at the pleading stage and dismissed claims concerning other statements; a second amended complaint was filed in January 2024. The company says it intends to defend the case.
- The financial statements received an unqualified KPMG audit opinion; the auditor reported no critical audit matters. Management concluded disclosure controls and internal control over financial reporting were effective, but the company was not required to obtain an auditor attestation on internal controls.
Important facts for investors to verify
- Subsequent YCANTH sales, prescriptions, distributor inventory, and realized net revenue, including actual gross-to-net adjustments and customer concentration.
- Cash runway assumptions, the pace of operating cash burn, and progress toward the revenue targets required to access additional OrbiMed borrowing.
- Commercial adoption, payer reimbursement, and the effect of Zelsuvmi and permitted compounded products on YCANTH demand.
- VP-315 trial results and the timing, cost, and FDA requirements for follow-on indication trials.
- Cantharidin and applicator supply continuity, as well as the feasibility and timing of commercial-scale synthetic supply.
- Developments in the securities litigation and any related financial exposure; the filing does not provide a clear quantified estimate of potential damages.